Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last ¥1,437 JPY
Change Today +59.00 / 4.28%
Volume 120.9K
As of 2:00 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

aska pharmaceutical co ltd (4514) Snapshot

Open
¥1,419
Previous Close
¥1,378
Day High
¥1,445
Day Low
¥1,386
52 Week High
08/3/15 - ¥1,655
52 Week Low
02/6/15 - ¥1,087
Market Cap
43.9B
Average Volume 10 Days
107.2K
EPS TTM
¥38.98
Shares Outstanding
30.6M
EX-Date
09/28/15
P/E TM
36.9x
Dividend
¥14.00
Dividend Yield
0.97%
Current Stock Chart for ASKA PHARMACEUTICAL CO LTD (4514)

Related News

No related news articles were found.

aska pharmaceutical co ltd (4514) Related Businessweek News

No Related Businessweek News Found

aska pharmaceutical co ltd (4514) Details

ASKA Pharmaceutical Co.Ltd. engages in the manufacture, sale, and import/export of pharmaceuticals, veterinary medicines, quasi-drugs, foods, and medical devices. The company offers Altat for the treatment of digestive ulcers and gastritis; Prostal drug for the treatment of benign prostatic hypertrophy and prostate cancer; Calcitoran, a synthetic salmon calcitonin formulation; Lipidil, an antihyperlipidemic agent; and Thyradin, a drug for the treatment of hypothyroidism. It is also developing BNP7787, an antineoplastic effect enhancer for antineoplastic drugs, which is in Phase III clinical trials in Europe, the United States, and Japan; and AKP-501, an infertility medication contains genetically modified follicle-stimulating hormone. In addition, it provides Menoaid Combipatch, a transdermally administered medication combining estrogen and progestin to relieve climacteric disturbances. ASKA Pharmaceutical Co., Ltd. was founded in 1920 and is headquartered in Tokyo, Japan.

862 Employees
Last Reported Date: 06/26/15
Founded in 1920

aska pharmaceutical co ltd (4514) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

aska pharmaceutical co ltd (4514) Key Developments

ASKA Pharmaceutical Co.Ltd., Annual General Meeting, Jun 26, 2015

ASKA Pharmaceutical Co.Ltd., Annual General Meeting, Jun 26, 2015.

ASKA Pharmaceutical Co.Ltd. to Report Fiscal Year 2015 Results on May 12, 2015

ASKA Pharmaceutical Co.Ltd. announced that they will report fiscal year 2015 results on May 12, 2015

ASKA Pharmaceutical Co.Ltd. to Report Q3, 2015 Results on Feb 04, 2015

ASKA Pharmaceutical Co.Ltd. announced that they will report Q3, 2015 results on Feb 04, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4514:JP ¥1,437.00 JPY +59.00

4514 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4514.
View Industry Companies
 

Industry Analysis

4514

Industry Average

Valuation 4514 Industry Range
Price/Earnings 35.3x
Price/Sales 0.9x
Price/Book 1.0x
Price/Cash Flow 38.2x
TEV/Sales 0.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASKA PHARMACEUTICAL CO LTD, please visit www.aska-pharma.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.